Anrotinib is anrotinib hydrochloride, which has therapeutic effects on small cell lung cancer and should be used under medical supervision. 1. Anrotinib hydrochloride belongs to multi-targeted receptor tyrosine kinase inhibitors, which can inhibit the proliferation of many tumor cell lines. It can be used in the treatment of small cell lung cancer, non-small cell lung cancer, clear cell sarcoma and other tumors. 2. Anrotinib hydrochloride is contraindicated in centralized squamous lung cancer, severe hepatic and renal insufficiency, hypersensitivity to the product, risk of hemoptysis, pregnancy, lactation. 3. Adverse reactions include hypertension, hand and foot skin reactions, fatigue, abnormal thyroid function, abnormal liver function, gastrointestinal reactions, hyperlipidemia, proteinuria and so on. Reasonable use of medication should be in accordance with medical advice.